• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stock Of The Day: It's No Coincidence CVS Health Stock Found Support Where It Did

    6/27/24 12:51:25 PM ET
    $CVS
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $CVS alert in real time by email

    CVS Health Corp (NYSE:CVS) shares are getting crushed because of the terrible earnings report from Walgreens Boot Alliance. Inc. (NASDAQ:WBA). Some investors fear CVS may experience some of the same issues that drove Walgreens lower.

    It isn't a coincidence CVS found support right around the important $57.60 level. And it’s not surprising either. It's an illustration of an important market dynamic that savvy traders use to profit. This is why it's our Stock of the Day.

    The best traders don't guess. They let the market tell them what to do. And the market “speaks” by how it reacts when an important price level has been reached.

    Resistance Becomes Support

    Price levels that had previously been resistance can convert into support levels.

    As seen on the chart, the $57.60 level was the top in May. And many people who sold there were happy they did so after the price fell lower.

    CVS Health Corporation (NYSE:<a class=CVS) found support at a level that was resistance." class="wp-image-409202" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/27115931/1-8-1024x596.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/27115931/1-8-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/27115931/1-8-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/27115931/1-8.png 1041w" sizes="(max-width: 1024px) 100vw, 1024px" />

    But then the stock ripped higher in early June and a number of these traders and investors started to think they made a mistake by selling. They decided to buy their shares back — but only at the same price they were sold.

    So, it isn't a coincidence that CVS found support at this level. A large number of these remorseful sellers placed buy orders right around $57.60. This large concentration of orders was enough to absorb all the selling and put a floor under the shares.

    Rebound Coming?

    Stocks tend to rally after they drop to support levels. This happens when some investors and traders who created the support with their buy orders become anxious.

    They sense other buyers are coming into the market. That's why the price has stopped moving lower.

    The sellers will go to whoever is willing to pay the highest price. Because some of these buyers don't want to miss the trade, they increase the prices they are willing to pay.

    Others see this and do the same. And it could result in a bidding war to force the shares higher.

    The ability to identify important prices levels for a stock is essential for successful trading. It helps to identify logical places to enter and exit positions.

    Photo: Around the World Photos via Shutterstock

    Get the next $CVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVS
    $WBA

    CompanyDatePrice TargetRatingAnalyst
    CVS Health Corporation
    $CVS
    3/12/2026$94.00Mkt Perform → Outperform
    Bernstein
    CVS Health Corporation
    $CVS
    10/14/2025$91.00Buy
    Goldman
    CVS Health Corporation
    $CVS
    8/18/2025$79.00Neutral → Buy
    UBS
    CVS Health Corporation
    $CVS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    Walgreens Boots Alliance Inc.
    $WBA
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    CVS Health Corporation
    $CVS
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    CVS Health Corporation
    $CVS
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    CVS Health Corporation
    $CVS
    1/30/2025Hold → Buy
    Edward Jones
    More analyst ratings

    $CVS
    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Shah Prem S

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    4/2/26 4:58:11 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Newman Brian

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    4/2/26 4:57:02 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Nelson Steven H

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    4/2/26 4:56:13 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $WBA
    SEC Filings

    View All

    SEC Form DEF 14A filed by CVS Health Corporation

    DEF 14A - CVS HEALTH Corp (0000064803) (Filer)

    4/3/26 4:05:26 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form DEFA14A filed by CVS Health Corporation

    DEFA14A - CVS HEALTH Corp (0000064803) (Filer)

    4/3/26 4:05:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Corporation filed SEC Form 8-K: Leadership Update

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    3/19/26 4:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVS Health upgraded by Bernstein with a new price target

    Bernstein upgraded CVS Health from Mkt Perform to Outperform and set a new price target of $94.00

    3/12/26 8:38:26 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Goldman initiated coverage on CVS Health with a new price target

    Goldman initiated coverage of CVS Health with a rating of Buy and set a new price target of $91.00

    10/14/25 8:48:20 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by UBS with a new price target

    UBS upgraded CVS Health from Neutral to Buy and set a new price target of $79.00

    8/18/25 8:45:28 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omnicare Advances Court-Supervised Process While Continuing to Deliver Enhanced Value to Customers

    Enters into Asset Purchase Agreement with GenieRx WOONSOCKET, R.I., April 1, 2026 /PRNewswire/ -- Omnicare, LLC (the "Company" or "Omnicare"), a subsidiary of CVS Health (NYSE:CVS), today announced it has entered into an asset purchase agreement with GenieRx Holdings LLC ("GenieRx"), a joint partnership between private investment firm Milrose Capital LLC and health-care investment and management firm Integro Asset Management LLC, which does business as Integro Healthcare Services. GenieRx will serve as the "stalking horse bidder" in the Company's ongoing court‑supervised sale process.

    4/1/26 3:07:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Pharmacy® celebrates opening of first pharmacy-only location in Chicago

    Small, dedicated neighborhood pharmacies to open in select communities to help increase access to convenient pharmacy care Openings are part of ongoing commitment to serve communities and meet consumers where they are WOONSOCKET, R.I., March 30, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) today unveiled the first of nearly 20 pharmacy-only, apothecary-style CVS Pharmacy® locations it plans to open this year to increase access to pharmacy care. The new pharmacy, located at 2628 West Pershing Road in Chicago's West End, will help bridge gaps in care and make it easier for community members to access medications, immunizations and other health care services provided by pharmacists.

    3/30/26 12:00:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., March 18, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 4, 2026, to holders of record on April 23, 2026. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary c

    3/18/26 5:15:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $WBA
    Financials

    Live finance-specific insights

    View All

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., March 18, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 4, 2026, to holders of record on April 23, 2026. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary c

    3/18/26 5:15:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Foundation Invests $2.24 Million to Strengthen Community Health in Charlotte's Historic West End

    Health Zones effort aims to improve health care access, healthy food and chronic condition support in CharlotteCHARLOTTE, N.C., March 18, 2026 /PRNewswire/ -- The CVS Health Foundation today announced the launch of its Health Zone in Charlotte with a $2.24 million investment in the Westside Wellness Collab, led by Local Initiatives Support Corporation (LISC) Charlotte to expand access to health care, healthy food and chronic condition support in Charlotte's Historic West End. "Families deserve access to quality care, healthy food and the support networks that make long‑term well

    3/18/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Highlights Total revenues increased to $105.7 billion, up 8.2% compared to prior yearGAAP diluted EPS of $2.30 and Adjusted EPS of $1.09Full-Year Highlights Total revenues increased to a record high $402.1 billion, up 7.8% compared to prior yearGAAP diluted EPS of $1.39 and Adjusted EPS of $6.75Generated cash flow from operations of $10.6 billionOperational Highlights CVS Pharmacy® successfully completed the transition to cost-based reimbursement across its Commercial, Third-Party Discount, Medicare and Medicaid businesses.Aetna® continues to improve the experience for health care professionals and their patients, approving more than 95% of all eligible prior authorizations wi

    2/10/26 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $WBA
    Leadership Updates

    Live Leadership Updates

    View All

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Aetna 2026 Medicare Advantage plans deliver access to affordable, personalized care

    Providing access to affordable care $0 copays on Tier 1 drugs & covered vaccines at in-network pharmacies1, $0 copay for colonoscopies and mammograms at in-network providers$0 copay for annual Healthy Home Visit from a licensed Signify Health clinicianContinued investment in technology, tools and teams that support our members Commitment to supporting unique member needs — those living with chronic conditions and individuals dually eligible for both Medicare and MedicaidLeveraging the strength of the CVS Health family of companies to deliver differentiated member experiencesWOONSOCKET, R.I., Oct. 1, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announced our 2026 Medi

    10/1/25 7:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreen Co. To Operate as Private Standalone Company Following Acquisition By Sycamore Partners

    Appoints Mike Motz as Chief Executive Officer Walgreen Co. ("Walgreens", or the "Company"), America's leading independent retail pharmacy, announced today that it is now operating as a private standalone company following its acquisition by Sycamore Partners ("Sycamore"), a leading private equity firm based in New York. Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in Walgreens, demonstrating their ongoing support and confidence in the Company's future. Mike Motz has been appointed as Chief Executive Officer of Walgreens effective immediately. Motz was formerly CEO of Staples US Retail, a Sycamore por

    8/28/25 8:31:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples